Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.50

-1.6%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (15793)	2/24/1998 5:29:00 PM
From: David L. Hachey	Read Replies (5) of 32384

Peter; Actually, it's a relatively simple marketing problem to have a single drug formulated in two (or more) vehicles. For example, a topical Targretin ointment could be used for Kaposi's sarcoma; it would be virtually useless for metabolic diseases like diabetes. Oral formulations could be made for breast cancer at a higher dose than indicated for diabetes, although this is a sticky problem if the doses are similar. Simply releasing them under different tradenames would also work. Most oncologists won't prescribe for diabetes, and conversely, endocrinologists won't likley treat cancer. No one has raised the issue of targretin use as a chemoprotective agent to supress the induction of breast cancer. Because of the way these drugs work to cure breast cancer, there is potentially a much wider indicated market in cancer prevention but at a lower dose. From what I can tell, targretin has remarkably few side effects. I wouldn't be surprised if the rat studies for such an indication aren't already in progress. Henry, care to comment. Regards, ...Dave Hachey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next